Several monoclonal antibodies (mAbs) against PD-L1 and PD-1 have demonstrated clinical benefit in patients with NSCLC and are collectively known as checkpoint inhibitors [98], [99], [100]. Here, CD274 is linked to non-small cell lung carcinoma.